Stock AKBA AKEBIA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
1.34 USD +0.75% Intraday chart for Akebia Therapeutics, Inc. -1.47% +8.06%
04-23 Averoa Seeks EU Approval for Chronic Kidney Disease Drug MT
04-16 Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement CI

Business Summary

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Number of employees: 167

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Therapeutics
100.0 %
292 100.0 % 195 100.0 % -33.46%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
292 100.0 % 195 100.0 % -33.46%

Managers

Managers TitleAgeSince
John Butler CEO
 Chief Executive Officer 59 30/06/13
Tracey Vetterick ADM
 Chief Administrative Officer - 31/03/22
Michel Dahan COO
 Chief Operating Officer 45 31/12/12
Steven Burke CTO
 Chief Tech/Sci/R&D Officer 63 16/06/19
Michael Rabinowitz CTO
 Chief Tech/Sci/R&D Officer - -
Mercedes Carrasco PRN
 Corporate Officer/Principal - -
Carolyn Rucci LAW
 General Counsel - 31/12/20
Meredith Bowman HRO
 Human Resources Officer - 30/04/22
Christian Barnes PRN
 Corporate Officer/Principal - -
Nicholas Grund PRN
 Corporate Officer/Principal 54 01-08

Members of the board

Members of the board TitleAgeSince
Michael Rogers BRD
 Director/Board Member 64 11/12/18
Adrian Adams CHM
 Chairman 73 11/12/18
LeAnne M. Zumwalt BRD
 Director/Board Member 65 15/02/21
John Butler CEO
 Chief Executive Officer 59 30/06/13
Steven Gilman BRD
 Director/Board Member 71 11/12/18
Ronald Frieson BRD
 Director/Board Member 65 31/10/21
Cynthia Smith BRD
 Director/Board Member 55 27/08/18
Myles Wolf BRD
 Director/Board Member 53 05/04/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 209,595,254 188,221,008 ( 89.80 %) 0 89.80 %

Shareholders

NameEquities%Valuation
Alerce Investment Management LP
5.518 %
11,552,558 5.518 % 21 M $
Vanguard Global Advisers LLC
3.633 %
7,607,472 3.633 % 14 M $
Acadian Asset Management LLC
3.303 %
6,915,503 3.303 % 13 M $
Renaissance Technologies LLC
2.283 %
4,779,383 2.283 % 9 M $
Muneer Satter
2.222 %
4,652,561 2.222 % 9 M $
Millennium Management LLC
1.242 %
2,599,987 1.242 % 5 M $
BlackRock Institutional Trust Co. NA
1.201 %
2,514,860 1.201 % 5 M $
John Butler
1.129 %
2,364,436 1.129 % 4 M $
Susquehanna Securities LLC
1.031 %
2,159,364 1.031 % 4 M $
Jacobs Levy Equity Management, Inc.
0.8869 %
1,856,925 0.8869 % 3 M $

Company contact information

Akebia Therapeutics, Inc.

245 First Street Suite 1400

02142, Cambridge

+617 871 2098

http://www.akebia.com
address Akebia Therapeutics, Inc.(AKBA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Akebia Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.34 USD
Average target price
5 USD
Spread / Average Target
+273.13%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AKEBIA THERAPEUTICS, INC. Stock Akebia Therapeutics, Inc.
+8.06% 281M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. AKBA Stock
  4. Company Akebia Therapeutics, Inc.